Long-Term Liabilities to Equity: Neuronetics, Inc (STIM)

Neuronetics, Inc. (STIM) develops devices for non-invasive brain stimulation to treat depression, offering an alternative to medication. The business relies on stable demand and insurance coverage, which minimizes the impact of crises. This daily price chart reflects the asset's dynamics, where the separate_debt_long_eq metric stands at 4.80. Future growth will depend on the organic expansion of the clinic network following the recent acquisition of a niche player.

Assessing long-term leverage is critical for minimizing bankruptcy risks when establishing a position, as the ratio of long-term debt to equity determines the sustainability of profitability. By analyzing the change in long-term debt to equity, an investor can see to what extent borrowed funds finance the expansion of brain stimulation systems and high-margin sales of disposable keys, which confirms the financial strength of Neuronetics, Inc. (STIM).